YSY01A, a novel proteasome inhibitor, induces cell cycle arrest on G2 phase in MCF-7 cells via ERα and PI3K/Akt pathways

Journal of Cancer

Volumn 6, Issue 4, 2015, Pages 319-326

  Xue, Bingjie ^a   Huang, Wei ^a   Yuan, Xia ^a   Xu, Bo ^a   Lou, Yaxin ^b   Zhou, Quan ^a   Ran, Fuxiang ^a   Ge, Zemei ^b   Li, Runtao ^b   Cui, Jingrong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

ERa; High content screening; Label free quantitative proteomics; MCF 7; PI3K Akt pathways; PS341; YSY01A

Indexed keywords

CYTOTOXIC AGENT; ESTROGEN RECEPTOR ALPHA; P21 ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG; YSY 01A;

ARTICLE; BREAST CANCER; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; M PHASE CELL CYCLE CHECKPOINT; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84923791525     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10733     Document Type: Article

References (44)

1. D'Arcy P, Linder S. Molecular pathways: translational potential of deubiquitinases as drug targets. Clin Cancer Res 2014; 20(15):3908-14.
2. Liu YB, Gao X, Deeb D, et al. Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancercells by pristimerin. Int J Oncol 2014; 45(4):1735-41.
3. Johnsen SA, Gungor C, Prenzel T, et al. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res 2009; 69(1):128-136.
4. Fan M, Nakshatri H, Nephew KP. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 2004; 18(11):2603-15.
5. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000; 5:939-48.
6. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERa lpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11(3):695-707.
7. Powers GL, Ellison-Zelski SJ, Casa AJ, et al. Proteasome inhibition represses ERa gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 2010; 29(10): 1509-1518.
8. Zhang H, Sun L, Liang J, et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated transcription. EMBO J 2006; 25:4223-33.
9. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006; 116(3):561-70.
10. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(2):101-12.
11. Josh Lauring, Ben Ho Park, Antonio C. Wolff. The Phosphoinositide- 3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. J Natl Compr Canc Netw 2013; 11(6):670-678.
12. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13(2):R21.
13. Mahadevan D., Chiorean E.G., Harris WB., et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2012; 48(18):3319-3327.
14. Liu CY, Shiau CW, Kuo HY, et al. Cancerous inhibitor of protein phosphatase 2A determines bortezomibinduced apoptosis in leukemia cells. Haematol 2013; 98(5):729-738.
15. Chen KF, Yeh PY, Yeh KH, et al. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008; 68(16):6698-6707.
16. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13(18 Pt 1): 5291-5294.
17. Morra E. Carfilzomib: a new opportunity for WM patients. Blood. Blood 2014; 124(4):468-9.
18. Mohty M, Brissot E, Savani BN, Gaugler B. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 2013; 19(10):1416-20.
19. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61(7):3071-3076.
20. Julian Adams. THE PROTEASOME: A SUITABLE ANTINEOPLASTIC TARGET. Nat Rev Cancer 2004; 4(5):349-60.
21. Nooka AK. Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib. Oncology (Williston Park) 2013; 1:27.
22. Sandra E. Kurtin, Elizabeth Bilotti. Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents. J Adv Pract 2013; 4(5):307-321.
23. Engel RH, Brown JA, Von Roenn JH, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007; 25(8):733-737.
24. Dees EC, Orlowski RZ. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol 2006; 2(1):121-135.
25. Xu-Hua Wang, Bo Xu, Jing-Tao Liu, Jing-Rong Cui. Effect of β-escin sodium on endothelial cells proliferation, migration and apoptosis. Vascular Pharmacology 2008; 49:158-165.
26. Ma W, Chen M, Kaushal S, et al. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. International Journal of Nanomedicine 2012; 7:1475-1487.
27. Kota KP1, Benko JG, Mudhasani R, et al. High Content Image Based Analysis Identifies Cell Cycle Inhibitors as Regulators of Ebola Virus Infection. Viruses 2012; 4(10):1865-1877.
28. Tarawneh R, Lee JM, Ladenson JH, et al. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012; 78(10):709-719.
29. Zimmer JS, Monroe ME, Qian WJ, Smith RD. Advances in proteomics data analysis and display using an accurate mass and time tag approach. Mass Spectrom Reviews 2006; 25(3):450-486.
30. Yan Fu, Li-Yun Xiu, Wei Ji, et al. AMT: A Statistical Algorithm for Fast Detection of Protein Modifications From LC-MS/MS Data. Technological Innovation and Resources 2011.
31. Hou L, Xu B, Guo W, et al. Pseudolaric acid B inhibits inducible cyclooxygenase- 2 expression via downregulation of the NF-κB pathway in HT-29 cells. J Cancer Res Clin Oncol 2012.
32. Boccadoro, M., Morgan, G. Cavenagh, J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell International 2005; 5(1):18.
33. Andreu-Vieyra C, Berenson JR. Carfilzomib in multiple myeloma. Expert Opin Biol Ther 2014; 29:1-15.
34. Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. British Journal of Haematology 2013; 162(5):657-669.
35. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J Mass Spectrom 2009; 44(12): 1637-1660.
36. Ibrahim AS, Sobh MA, Eid HM, et al. Gingerol-derivatives: emerging new therapy against human drug-resistant MCF-7. Tumour Biology 2014; 4(2):39-47.
37. Engelman JA1, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics 2006; 7(8):606-19.
38. Claire Gourzones-Dmitriev, alboukadel Kassambara, Surinder Sahota, et al. DNA repair pathways in human multiple myeloma. Cell cycle 2013; 12(17):2760-2773.
39. Roman Hajek, David Siegel, Robert Z. Orlowski, et al. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leukemia & Lymphoma 2014; 55(1):11-18.
40. Iida S, Ri M. Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance tobortezomib in multiple myeloma. Rinsho Ketsueki 2014 Mar; 55(3):304-10.
41. Trinh XB, Sas L, Van Laere SJ, et al. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncology Reports 2012; 27(3):657-63.
42. Erstad DJ, Cusack JC Jr. Targeting the NF-κB pathway in cancer therapy. Surg Oncol Clin N Am 2013; 22(4):705-46.
43. Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid 2013; 23(2):209-18.
44. Maynadier M, Shi J, Vaillant O, et al. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells. Molecular Mol Cancer Res 2012; 10(11):1473-81.